Pharmacological modification of recovery following brain injury

Neurology Report

Volumn 27, Issue 3, 2003, Pages 129-137

  Flanagan, Steven R ^a   Kane, Leslie ^b   Rhoades, Daniella ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85015462265     PISSN: 1085049X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01253086-200327030-00008     Document Type: Article

References (98)

1. Marshall JF. Neural plasticity and recovery of function after brain injury. Int Rev Neurobiol. 1985;26:201-247.
2. Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neo-cortical neural sprouting, synaptogcnesis, and behavioral recovery with D-amphetamine therapy after neo-cortical infarction in rats. Stroke. 1998;29:2381-2393.
3. Dunwiddie TV, Roberson NL, Worth T. Modulation of long term potentiation. Effects of adrenergic and neuroleptic drugs. Pharmacol Biochem Befoav. 1982; 17: 1257-1264.
4. Aston-Jones G, Chiang C, Alexinsky T. Discharge of noradrenergic locus ceruleus neurons in behaving rats and monkeys suggesting a role in vigilance.Prog Brain Res. 1991;88:501-520.
5. Carli M, Robbins TW, Evenden JL, Everitt BJ. Effects of lesions to ascending noradrenergic neurons on performance on a 5-choice serial reaction task in rats: implications for theories of dorsal noradrenergic bundle function based on selective attention. Behav Brain Res. 1983;9:361-380.
6. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidence by c-fos immunocyto-chemistry in the cat. Proc Batl Acad Sci. 1996;93: 14128-14133
7. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20: 8620-8628.
8. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol and experience interact to affect the rate of recovery after motor cortex injury. Science. 1982; 217:885-887.
9. Hovda DA, Feeney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res. 1984; 298:358-361.
10. Kline AE, Chen MJ, Tso-Olivas DY, Feeney DM. Methylphenidate treatment following ablation-induced hemiplegia in nit: experience during drug action alters effects on recovery of function. Pharmacol Biochem Behav. 1994;48:773-779.
11. Schmanke T, Barth TM. Amphetamine and task-specific practice augment recovery of vibrissae-evoked forelimb placing after unilateral sensorimotor cortical injury in the rat.J Neurotrauma. 1997;14:459-468.
12. Kikuchi K, Nishino K, Ohyu. Increasing CNS norepinephrine levels by the precursor L-DOPS facilitates beam-walking recovery after sensorimotor cortex ablation in rats. Brain Res. 2000;860:130-135.
13. Hovda DA, Sutton RL, Feeney DM. Amphetamine-induced recovery of visual cliff performance after bilateral visual cortex ablation in cats: measurements of depth perception thresholds. Behav Neurosci. 1989; 103:574-585.
14. Kolb B, Sutherland R. Noradrenaline depletion blocks behavioral sparing and alters cortical morphogenesis after neonatal frontal cortex damage in rats. J Neurosci. 1992;12:2221-2230.
15. Sutherland RJ, Kolb B, Wliishaw IQ, Becker JB. Cortical noradrenaline depletion eliminates sparing of spatial learning after neonatal frontal cortex damage in the rat. Neuroscience Letter. 1982;32:125-130.
16. Hovda DA, Feeney DM. Haloperidol blocks amphetamine induced recovery of binocular depth perception after bilateral visual cortex ablation in cats. Proc West Pharmacol Soc. 1987;28:209-211.
17. Feeney DM, Westerberg VS. Norepinephrine and brain damage:Alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol. 1990;44:233-252.
18. Goldstein LB, Davis JN. Clonidine impairs recovery of beam-walling after a sensorimotor cortex lesion in the rat.Brain Res. 1990;508:305-309.
19. Stephens J, Goldberg G, Demopoulos JT. Clonidine reinstates deficits following recovery from sensorimotor cortex lesions in rats. Arch Phys Med Rebabil. 1986; 67:666-667.
20. Boyeson MG, Feeney DM. Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. Pharmacol Biochem Behav. 1990;35: 497-501.
21. Butefisch CM, Davis BC, Sawaski L, et al. Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol. 2002;51:59-68.
22. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerated motor recovery after stroke. Further evidence. Stroke. 1995;26:2254-2259.
23. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylpheinate in early post-stroke recovery:a double-blind, placebo-controlled study. Arch Phys Med Rehabil. 1998;79:1047-1050.
24. Walker-Batson D, Curtis S, Natarajan R, et al. A doubleblind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke. 2001;32:2093-2098.
25. Lipper S, Tachman MM. Treatment of chronic post-traumatic organic brain syndrome with dextroamphetamine: first report case.J Nerv Ment Dis. 1976;162:366-371.
26. Evans RW, Ciualtieri CT, Paterson D. Treatment of chronic closed head injury with psychostimulant drugs.A controlled case study with an appropriate evaluation of procedure. J Nerv Ment Dis. 1987; 175:106-110.
27. Gualtieri CT, Evans RW. Stimulant treatment for the neuro-behavioral sequelae of traumatic brain injury. Brain Inj. 1988:2:273-290.
28. Hornstein A, Lennihan L Seliger G, Lichtman S, Schroeder K. Amphetamine in recovery from brain injury. Brain Inj. 1996; 10:145-148.
29. Whyte J, Hart T, Schuster K, Fleming M, Polansky M, Coslett HB. Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. Am J Phys Med Rehabil. 1997; 76:440-450.
30. Whyte J, Vaccaro M, Grieb-Neff P, Hart T. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. Brain Inj. 2002;17:284-299.
31. Bleiberg J, Garmoc W, Cederquist J, et al. Effect of Dexedrine on performance consistency following brain injury: A double blind placebo crossover case study. Neuropsychiatry Neuropsychol Behav Neurol. 1993;6: 245-248.
32. Mahalick D, Carmel P, Greenberg J, et al. Psychophar-macological treatment of acquired attention disorder in children with brain injury. Pediatr Neurosurg. 1998; 29:121-126.
33. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444-451.
34. Damian MS, Gerlach A, Schmidt F, Lehmann E, Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology. 2001;56:794-796.
35. MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology. 2002; 59:1876-1880.
36. Rammohan KW Rosenberg JH, Lynn DJ, Blumenfeld AM, Poliak CP, Nagaraja HN. Efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72:179-183.
37. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open label study. J Neurol. 2002;249:983-987.
38. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open label study. J Am Acad Child Adolesc Psychiatry. 2001; 40:230-235.
39. Melamed S, Stern M, Rahmani L, Groswasser Z, Najenson T. Attention capacity limitation, psychiatric parameters and their impact on work involvement following brain injury. Scan J Rehabil Med. Suppl 1985;12:21-26.
40. Goldstein LB. Common drugs may influence motor recovery after stroke. The Sygen in acute stroke study investigators. Neurology. 1995;45:865-871.
41. Goldstein LB. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry. 1995;58:753-755.
42. Goldstein LB. Physician prescribing patterns after ischemic stroke. Neurology. 1988; 38:1806-1809.
43. Giantusos G, Chute S, Dunn JA. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985; 110:357-361.
44. Allen RM. Role of amantadine in the management of neuroleptic-induced extra-pyramidal syndromes: Overview and pharmacology. Clin Neuropharmacol. 1983;6 (suppl):564-573.
45. Liu XH, Kato H, Chen T, Kato K, Itoy ama Y. Bromocriptine protects against delayed neuronal death of hip-pocampampal neurons following ischemia in the ger-bil. J Neurol Sci. 1995;129:9-14.
46. Kline AE, Massucci JL, Marion DW, Dixon CE. Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. J Neurotrauma. 2002;19:415-425.
47. Wilkinson R, Meythaler JM, Guin-Renfroe S. Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj. 1999;13:1025-1031.
48. Karli DC, Burke DT, Kim HK, et al. Effects of dopamine combination therapy for frontal lobe dysfunction in traumatic brain injury. Brain Inj. 1999;13:63-68.
49. Rosati DL. Early polyneuropharmacologic intervention in brain injury agitation. AmJ Phys Med Rehabil. 2002; 81:90-93.
50. Beaumont A, Hayasaki K, Marmarou A, Barzo P, Fatouros P, Corwin F. Contrasting effects of dopamine therapy in experimental brain injury. J Neurotrauma. 2001;18: 1359-372.
51. Passler MA, Riggs RV. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil. 2001;82:311-315.
52. Zafonte RD, Watanabe T, Mann NR. Amantadine:A potential treatment for the minimally conscious state. Brain Inj. 1998;12:617-621.
53. Haig AJ, Ruess JM. Recovery from vegetative state of six months’ duration associated with Sinemet (levodopa/ carbidopa). Arch Phys Med Rehabil. 1990;71:1081-1083.
54. Alexander MP. Chronic akinetic mutism after mesencephalic-diencephalic infarction: Remediated with dopaminergic medications. Neurorehabil Neural Repair. 2001;15:151-156.
55. Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj. 1994;8:709-718.
56. Edby K, Larson J, Eek M, von Wendt L, Ostergard B. Amantadine treatment of a patient with anoxic brain injury. Child’s Nerv Syst. 1995; 11:607-609.
57. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry. 1997;9:222-230.
58. MsDowell S, Whyte J, D’Esposito M. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain. 1998; 121:1155-1164.
59. Meythaler JM, Brunner RC, Johnson A, Novack T. Amantadine to improve neurorecovery in traumatic brain-associated diffuse axonal injury: A pilot doubleblind randomized trial. J Head Trauma Rehabil. 2002; 17:300-313
60. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: A new clinical profile for traumatic brain injury. Clin Neurophartnacol. 1989;12:258-270.
61. Van Reekum R, Bayley M, Garner S, et al. N of 1 study: amantadine for the amotivation syndrome in patient with traumatic brain injury. Brain Inj. 1995;9:49-53
62. Powell JH, al-Adawi S, Morgan J, Greenwood RJ. Motivational deficits after brain injury: Effects of bromocriptine in 11 patients. J Neurol Neurosurg Psychiatry. 1996;60:416-421.
63. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of lev-odopa in combination with physiotherapy on functional motor recovery after stroke: A prospective, randomized, double-blind study. Lancet. 2001;358:787-790.
64. Inversen SD. Behavioural effects of manipulation of basal ganglia neurotransmitters. Ciba Found Symp. 1984;107:183-200.
65. Vargo JM, Bromberg BB, Best PJ, Corwin JV, Marshall JF. D-l class dopamine receptor involvement in the behavioral recovery from prefrontal cortical injury. Behav Brain Res. 1995;72:39-48.
66. Fleet WS, Valenstein E, Watson RJ, Heilman KM. Dopamine agonist therapy for neglect in humans. Neurology. 1987;37:1765-1770.
67. Hurford P, Stringer AY, Jann B. Neuropharmacological treatment of hemineglect: A case report comparing bromocriptine and methylphenidate. Arch Phys Med Rehabil. 1998;79:346-349.
68. Geminiani G, Bottini, Sterzi R. Dopaminergic stimulation in unilateral neglect. J Neurol Neurosurg Psych-iatry. 1998;65:344-347.
69. Mukand JA, Guilmette TJ, Allen DG, et al. Dopaminergic therapy with carbidopa L-dopa for left neglect after stroke: A case series. Arch Phys Med Rehabil. 2001;82: 1279-1282.
70. Grujic Z, Mapstone M, Gitelman DR, et al. Dopamine agonists reorient exploration away from the neglected hemispace. Neurology. 1998;51:1395-398.
71. Barrett AM, Crucian GP, Schwartz RL, Heilman KM. Adverse effect of dopamine agonist therapy in a patient with motor-intentional neglect. Arch Phys Med Rehabil. 1999;80:600-603.
72. Shao L, Ciallella JR, Yan HQ, et al. Differential effects of traumatic brain injury of vesicular acetylcholine transporter and MS muscarinic receptor mRNA and protein in nx. J Neurotrauma. 1999;16:555-556.
73. Pike BR, Hamm RJ. Postinjury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats. Brain Res. 1995;686:37-43.
74. O'Dell DM, Hamm RJ. Chronic postinjury administration of MDL 26,479 (suritozole), a negative modulator of GABA A receptor, and cognitive impairment in rats following traumatic brain injury.J Neurosurg. 1995;83: 878-883.
75. Dixon CE, Ma X, Marion DW. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma. 1997; 14:161-169.
76. Rusted JM, Warburton DM. Cognitive models and cholinergic rugs. Neuropsychology. 1989;21:31-36.
77. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-417.
78. Muramoto O, Sugishita, Sugita H, Toyokura Y. Effect of pliysostigmine on constructional and memory tasks in Alzheimer’s disease. Arch Neurol. 1979;36:501-503
79. Thai LJ, Fuld PA, Masur DM, Sharpless NS. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol. 1983;13:491-496.
80. Thai LJ, Masur DM, Sharpless NS, Fuld PA., Davies P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer’s disease. Prog Neuropsychophannacol Biol Psychiatry. 1986;10:627-636.
81. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992;327:1253-1259.
82. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial.The Donepezil Study Group. Dementia. 1996;7:292-303
83. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer's disease: a 15 week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998; 158:1021-1031.
84. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of Acetylcholinestease inhibitor inpatients with mild to moderately severe Alzheimer’s disease. Prog Brain Res. 1993;98:431-438.
85. Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International radomised controlled trial. Br Med J. 1999;318:633-638.
86. Pomerleau OF. Nicotine as a psychoactive drug, anxiety and pain reduction. Psychopharmacology. 1986;22: 865-869.
87. Wesnes K, Revell A. The separate and combined effects of scopolamine and nicotine in human information processing. Psychopharmacology. 1984;20:5-11.
88. White HK, Levin ED. Four-week nicotine skin patch treatment on cognitive performance in Alzheimer’s disease. Psychoparmacology (Berl). 1999;143:158-165.
89. Levin HS. Treatment of postcpmcussional symptoms with CDP-choline J Neurol Sci. 1991;103:S39-S42.
90. Lozano R. CDP-Choline in the treatment of cranio encephalic trauma. J Neurol Sci. 1991; 103:S43-S47.
91. Leon-Carrion J, Dominguez-Roldan JM, Murill-Cabezas F, del Rosario Dominguez-Morales M, Munoz-Sanchez MA. The role of citicholine in neuropsychological training after traumatic brain injury. Neurorehabilitation. 2000;14:33-40.
92. Eames P, Sutton A. Protracted post-traumatic confusional state treated with physostigmine. Brain Inj. 1995;9: 729-734.
93. Weinberg RM, Auerbach SH, Moore S. Pharmacologic treatment of cognitive deficits: a case study. Brain Inj. 1987;1:57-59.
94. Cardenas DD, McLean A, Farrell-Roberts L, Baker L, Broole M, Haselkom J. Oral physostigmine & impaired memory in adults with brain injury. Brain Inj. 1994; 8:579-587.
95. Taverni JP, Seliger G, Lichtman SW. Donepezil mediated memory improvement in traumatic brain injury during postacute rehabilitation. Brain Inj. 1998; 12:77-80.
96. Bourgeois JA, Bahadur N, Minhjares S. Letter: Donepezil for cognitive deficits following traumatic brain injury: A case report J Neuropsychiatry. 2002; 14:463.
97. Whelan FJ, Walker MS, Schultz SK. Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann Clin Psychiatry. 2000; 12: 131-135.
98. Masanic CA, Bay ley MT, vanReekum R, Simmard M. Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil. 2001;82:896-901.